Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OBIO
OBIO logo

OBIO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Orchestra Biomed Holdings Inc (OBIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.990
1 Day change
3.10%
52 Week Range
5.420
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Orchestra Biomed Holdings Inc (OBIO) is not a strong buy at the moment given the lack of clear upward momentum, absence of significant positive catalysts in the short term, and the neutral sentiment from hedge funds and insiders. While the long-term potential is promising due to regulatory progress and strategic capital, the current technical and trading indicators suggest a wait-and-see approach for a beginner investor with a long-term focus.

Technical Analysis

The MACD is positive and expanding slightly, indicating mild bullish momentum. However, the RSI is neutral at 53.755, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 3.844, and resistance is at 4.123. The stock is in a consolidation phase with no clear breakout signals.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
9

Positive Catalysts

  • Regulatory progress with FDA approval of a reduced Phase 3 sample size and a de-risked PMA pathway with Medtronic. Secured $35M in strategic capital and received a second Breakthrough Device Designation. Analysts maintain a Buy or Overweight rating with price targets significantly above the current price.

Neutral/Negative Catalysts

  • No significant trading trends from hedge funds or insiders. The stock shows a 40% chance of declining in the short term (-3.06% in the next day, -1.18% in the next week, -2.64% in the next month). No recent news or congress trading data to drive sentiment.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are positive, with B. Riley lowering the price target to $10 (from $12) but maintaining a Buy rating, and Barclays raising the price target to $13 (from $12) with an Overweight rating. The long-term outlook is positive, supported by regulatory progress and strategic partnerships.

Wall Street analysts forecast OBIO stock price to rise
4 Analyst Rating
Wall Street analysts forecast OBIO stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.870
sliders
Low
10
Averages
14.25
High
20
Current: 3.870
sliders
Low
10
Averages
14.25
High
20
B. Riley
B. Riley
Buy
downgrade
$12 -> $10
AI Analysis
2026-05-19
Reason
B. Riley
B. Riley
Price Target
$12 -> $10
AI Analysis
2026-05-19
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Orchestra BioMed (OBIO) to $10 from $12 and keeps a Buy rating on the shares. Orchestra BioMed reported Q1 results alongside key regulatory and trial updates for its BACKBEAT program, including FDA approval of a reduced Phase 3 sample size, continued targeting of enrollment completion by Q3 and primary endpoint data in 2Q27, while also securing $35M in committed strategic capital and receiving a second Breakthrough Device Designation, the analyst tells investors in a research note. The clarified PMA pathway with its partner Medtronic (MDT) supports a more de-risked regulatory timeline and potential royalty-driven commercialization beginning in 2028, the firm says.
Barclays
Matt Miksic
maintain
$12 -> $13
2026-05-13
Reason
Barclays
Matt Miksic
Price Target
$12 -> $13
2026-05-13
maintain
Reason
Barclays analyst Matt Miksic raised the firm's price target on Orchestra BioMed to $13 from $12 and keeps an Overweight rating on the shares. The company's better than expected Q1 report included a positive update on the BACKBEAT pivotal trial, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OBIO
Unlock Now

People Also Watch